We are live on ! Find out more
SCLN

Sciclone Pharmaceuticals Inc
SCLN

Delisted

SCLN was delisted on the 13th of October, 2017.

Back to rankings

0 hedge funds and large institutions have $0 invested in Sciclone Pharmaceuticals Inc in 2017 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 128 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 129 → 0 (-129)

100% less funds holding in top 10

Funds holding in top 10: 3 → 0 (-3)

100% less capital invested

Capital invested by funds: $394M → $0 (-$394M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 128

Holders
–
Holders Change
-129
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
128
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$82.1M
2
Vanguard Group
Vanguard Group
Pennsylvania
-$33.3M
3
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$32.3M
4
GP
GLG Partners
United Kingdom
-$29M
5
State Street
State Street
Massachusetts
-$18.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
– -$82.1M -7,330,329 Closed
Vanguard Group
2
Vanguard Group
Pennsylvania
– -$33.3M -2,972,383 Closed
Dimensional Fund Advisors
3
Dimensional Fund Advisors
Texas
– -$32.3M -2,885,725 Closed
GP
4
GLG Partners
United Kingdom
– -$29M -2,586,437 Closed
State Street
5
State Street
Massachusetts
– -$18.5M -1,650,696 Closed
AQR Capital Management
6
AQR Capital Management
Connecticut
– -$11.5M -1,030,748 Closed
Two Sigma Investments
7
Two Sigma Investments
New York
– -$9.48M -846,803 Closed
MWNA
8
Marshall Wace North America
New York
– -$9.28M -843,451 Closed
Bank of New York Mellon
9
Bank of New York Mellon
New York
– -$8.94M -798,073 Closed
Northern Trust
10
Northern Trust
Illinois
– -$7.7M -687,426 Closed
Morgan Stanley
11
Morgan Stanley
New York
– -$7.47M -667,064 Closed
JP Morgan Chase
12
JP Morgan Chase
New York
– -$7.38M -661,789 Closed
Two Sigma Advisers
13
Two Sigma Advisers
New York
– -$6.16M -550,339 Closed
WAM
14
Wolverine Asset Management
Illinois
– -$6.16M -549,765 Closed
GH
15
GAM Holding
Switzerland
– -$6.06M -541,025 Closed
NI
16
Numeric Investors
Massachusetts
– -$5.8M -517,518 Closed
Geode Capital Management
17
Geode Capital Management
Massachusetts
– -$5.7M -508,551 Closed
Charles Schwab
18
Charles Schwab
California
– -$4.78M -426,549 Closed
AC
19
Athos Capital
Hong Kong
– -$4.6M -410,389 Closed
QI
20
QS Investors
New York
– -$4.59M -409,912 Closed
OAM
21
Oxford Asset Management
United Kingdom
– -$4.46M -400,000 Closed
Principal Financial Group
22
Principal Financial Group
Iowa
– -$4.42M -395,044 Closed
MC
23
Menta Capital
California
– -$4.18M -373,523 Closed
FPF
24
FNY Partners Fund
New York
– -$3.76M -335,900 Closed
State of Wisconsin Investment Board
25
State of Wisconsin Investment Board
Wisconsin
– -$3.45M -308,200 Closed
1
2 3 4 5

SCLN Hedge Fund Activity: Q4 2017 in Review

0 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Sciclone Pharmaceuticals Inc (SCLN) for Q4 2017, worth a combined $0 — down 100% from $394M a quarter earlier.

Sellers outnumbered buyers: 128 funds closed out of SCLN and 0 opened new positions — a net loss of 128 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was BlackRock, exiting entirely with an estimated $82.1M sold.

  • 0 institutional investors held Sciclone Pharmaceuticals Inc (SCLN) as of Q4 2017, down from 129 in Q3 2017.
  • Funds reported $0 of Sciclone Pharmaceuticals Inc stock for Q4 2017, down 100% quarter-over-quarter.
  • 0 funds opened new Sciclone Pharmaceuticals Inc positions in Q4 2017 and 128 closed out, a net change of -128 holders.
  • The largest Sciclone Pharmaceuticals Inc seller in Q4 2017 was BlackRock, an estimated $82.1M sold.

Based on aggregated 13F filings for Q4 2017.